Capgemini

Note: This is a daily stock update and the information stands true as of 28/10/25, 09:00 CET.

Company Update:
Q3 sales came in at €5.4bn (+2% lfl). Order intake at +1.5% lfl. FY Guidance increased:  Revenue is now expected to grow between +2.0% and +2.5% at constant exchange rates (vs. -1.0% to +1.0% previously), while the operating margin is slightly refined to 13.3%–13.4% (vs. 13.3%–13.5%). The organic free cash flow target remains unchanged at €1.9bn.

Expert Opinion: 
Momentum seems to start improving. Stock has been hammered over the last couple of years and trades at very attractive valuation ratios. With PE 25 and 26 at 13.4x and 11.9x. Strong buy in our expert's opinion. 


For daily updates, subscribe to our newsletter and for detailed information, reach out to us at sales@alphavalue.eu
Subscribe to our blog


Let’s talk
Interested in our research and want to learn more?
Alphavalue Morning Market Tip
Another late-stage clinical trial setback for AstraZeneca.
Alphavalue Morning Market Tip
Average H1 26 results, Belron strategic review (IPO) and new CEO.
Alphavalue Morning Market Tip
Strong Q2 (May-July) and encouraging trading statement for August.